Vor Bio announces final two-year results from Phase 3 TELIGAN trial of telitacicept in IgA nephropathy

Vor Bio announced final two-year results from the Phase 3 TELIGAN trial evaluating telitacicept in adults with IgA nephropathy, saying the trial met its Stage B primary endpoint.

Detected & updated continuously · Source: Nebula